SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.

@article{Sarrazin2007SCH5A,
  title={SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.},
  author={Christoph Sarrazin and R{\'e}gine Rouzier and Frank Wagner and Nicole Forestier and Dominique Larrey and Samir K Gupta and Musaddeq Hussain and Amrik Shah and David Cutler and Jenny R Zhang and Stefan Zeuzem},
  journal={Gastroenterology},
  year={2007},
  volume={132 4},
  pages={1270-8}
}
BACKGROUND & AIMS SCH 503034 is a novel and potent oral hepatitis C virus (HCV) protease inhibitor. In this phase Ib study, we assessed safety parameters and virologic response of combination of SCH 503034 plus pegylated (PEG) interferon (IFN) alpha-2b in patients with HCV genotype 1 infections who were previously nonresponders to PEG-IFN-alpha-2b +/- ribavirin therapy. METHODS This was a multicenter, open-label, 2-dose level, 3-way crossover, randomized (to crossover sequence) study carried… CONTINUE READING